登革热疫苗：未来的一项宝贵资产。
Dengue vaccine: a valuable asset for the future.
作者信息
Jindal Harashish, Bhatt Bhumika, Malik Jagbir Singh, S K Shashikantha
机构信息
a Department of Community Medicine; PGIMS; Rohtak, Haryana, India.
出版信息
Hum Vaccin Immunother. 2014;10(8):2245-6. doi: 10.4161/hv.28953.
Dengue has emerged as one of the major global public health problems. The disease has broken out of its shell and has spread due to increased international travel and climatic changes. Globally, over 2.5 billion people accounting for >40% of the world's population are at risk from dengue. Since the 1940s, dengue vaccines have been under investigation. A live-attenuated tetravalent vaccine based on chimeric yellow fever-dengue virus (CYD-TDV) has progressed to phase III efficacy studies. Dengue vaccine has been found to be a cost-effective intervention to reduce morbidity and mortality. Current dengue vaccine candidates aim to protect against the 4 dengue serotypes, but the recent discovery of a fifth serotype could complicate vaccine development. In recent years, an urgent need has been felt for a vaccine to prevent the morbidity and mortality from this disease in a cost-effective way.
登革热已成为全球主要的公共卫生问题之一。由于国际旅行增加和气候变化，这种疾病已突破其局限并蔓延开来。在全球范围内，超过25亿人，占世界人口的40%以上，面临登革热风险。自20世纪40年代以来，登革热疫苗一直在研究中。一种基于嵌合黄热病-登革热病毒的减毒活四价疫苗（CYD-TDV）已进入III期疗效研究阶段。登革热疫苗已被证明是一种具有成本效益的降低发病率和死亡率的干预措施。目前的登革热候选疫苗旨在预防4种登革热血清型，但最近发现的第五种血清型可能会使疫苗研发复杂化。近年来，人们迫切需要一种以具有成本效益的方式预防这种疾病的发病率和死亡率的疫苗。
Zotero 插件